role in atherogenesis, in part because of its effects on macrophage recruitment and retention ( 7,8 ). Initial oxidation of LDL and formation of what is often referred to as "minimally modifi ed" LDL stimulate adjacent endothelial and smooth muscle cells to release monocyte chemotactic protein-1, which facilitates the recruitment of monocytes into the arterial wall. OxLDL itself is chemotactic for monocytes by virtue of its lysophosphatidylcholine content.At high concentrations, oxLDL can be toxic to cultured macrophages and other cells, but at lower concentrations, it has been clearly shown to promote macrophage proliferation and inhibit apoptosis ( 9-15 ). Our group has recently reported that oxLDL inhibits macrophage apoptosis by activating eukaryotic elongation factor-2 (eEF2) kinase (also known as Ca 2+ /calmodulin-dependent kinase III) ( 16 ). eEF2 kinase activation and inhibition of macrophage apoptosis is mediated by an oscillatory increase in intracellular calcium ([Ca 2+ ] i ). However, the signal transduction pathways involved in oxLDL-mediated [Ca 2+ ] i oscillations have not been elucidated. Ca 2+ is a ubiquitous intracellular signal responsible for controlling numerous cellular processes. These processes range from muscle contraction to synaptic transmission and from cellular proliferation to apoptosis ( 17 ). Ca 2+ can relay specifi city in signaling through its high degree of spatial and temporal diversity ( 18 ) Atherosclerosis is a chronic infl ammatory disease of large and medium-sized arteries, and macrophages play a central role in its initiation and progression ( 1, 2 ). The accumulation of macrophages in lesions is due in part to recruitment of monocytes from the bloodstream ( 2 ) and to proliferation of macrophages within atherosclerotic lesions ( 3-6 ). Oxidized LDL (oxLDL) plays an important Abbreviations: BMDM, bone marrow-derived macrophage; [Ca 2+ ] i , intracellular calcium; DPBS, Dulbecco's phosphate-buffered saline; eEF2, eukaryotic elongation factor-2; ER, endoplasmic reticulum; IP 3 R, inositol-1,4,5-triphosphate receptor; LCM, L929 cell conditioned media; lysoPC, lysophosphatidylcholine; MAPK, mitogen-activated protein kinase; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; oxLDL, oxidized low density lipoprotein; PC, phosphatidylcholine; PLC, phospholipase C; PMS, phenazine methosulfate; RyR, ryanodine receptor; S1P, sphingosine-1-phosphate; SCaMPER, sphingolipid Ca 2+ release mediating protein of the endoplasmic reticulum; SERCA, sarco-endoplasmic reticulum ATPase; SK, sphingosine kinase; SKI, sphingosine kinase inhibitor.